Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

ACOG

· 2016 · Obstetrics & Gynecology

Abstract

The incidence of cervical cancer in the United States has decreased more than 50% in the past 30 years because of widespread screening. In 1975, the rate was 14.8 per 100,000 women. By 2011, it decreased to 6.7 per 100,000 women. Mortality from the disease has undergone a similar decrease from 5.55 per 100,000 women in 1975 to 2.3 per 100,000 women in 2011 (1). The American Cancer Society (ACS) estimated that there would be 12,900 new cases of cervical cancer in the United States in 2015, with 4,100 deaths from the disease (2). Cervical cancer is much more common worldwide, particularly in countries without screening programs, with an estimated 527,624 new cases of the disease and 265,672 resultant deaths each year (3). When cervical cancer screening programs have been introduced into communities, marked reductions in cervical cancer incidence have followed (4, 5).New technologies for cervical cancer screening continue to evolve, as do recommendations for managing the results. In addition, there are different risk-benefit considerations for women at different ages, as reflected in age-specific screening recommendations. In 2011, the ACS, the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) updated their joint guidelines for cervical cancer screening (6), as did the U.S. Preventive Services Task Force (USPSTF) (7). Subsequently, in 2015, ASCCP and the Society of Gynecologic Oncology (SGO) issued interim guidance for the use of a human papillomavirus (HPV) test for primary screening for cervical cancer that was approved in 2014 by the U.S. Food and Drug Administration (FDA) (8). The purpose of this document is to provide a review of the best available evidence regarding the prevention and early detection of cervical cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aog.0000000000001708

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 106

  1. Siegel, 2015, Cancer statistics, 2015, CA Cancer J Clin, 65, 5, 10.3322/caac.21254 · DOI · Paper page
  2. Gustafsson, 1997, International incidence rates of invasive cervical cancer before cytological screening, Int J Cancer, 71, 159, 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-# · doi:10.1002/(sici)1097-0215(19970410)71:2<159::aid-ijc6>3.0.co;2-#
  3. Gustafsson, 1997, International incidence rates of invasive cervical cancer after introduction of cytological screening, Cancer Causes Control, 8, 755, 10.1023/A:1018435522475 · DOI · Paper page
  4. Saslow, 2012, American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee, CA Cancer J Clin, 62, 147, 10.3322/caac.21139 · DOI · Paper page
  5. Moyer, 2012, Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. U.S. Preventive Services Task Force [published erratum appears in Ann Intern Med 2013;158:852], Ann Intern Med, 156, 880, 10.7326/0003-4819-156-12-201206190-00424 · DOI · Paper page
  6. Huh, 2015, Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance, Obstet Gynecol, 125, 330, 10.1097/AOG.0000000000000669 · DOI · Paper page
  7. Sung, 2000, Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan, Cancer, 88, 2283, 10.1002/(SICI)1097-0142(20000515)88:10<2283::AID-CNCR12>3.0.CO;2-D · DOI · Paper page
  8. Leyden, 2005, Cervical cancer in women with comprehensive health care access: attributable factors in the screening process, J Natl Cancer Inst, 97, 675, 10.1093/jnci/dji115 · DOI · Paper page
  9. Spence, 2007, Process of care fail- ures in invasive cervical cancer: systematic review and meta-analysis, Prev Med, 45, 93, 10.1016/j.ypmed.2007.06.007 · DOI · Paper page
  10. Sabatino, 2015, Cancer Screening Test Use — United States, 2013, MMWR Morb Mortal Wkly Rep, 64, 464
  11. Wright, 2003, Adding a test for human papillomavirus DNA to cervical-cancer screening, N Engl J Med, 348, 489, 10.1056/NEJMp020178 · DOI · Paper page
  12. Schiffman, 2003, Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia, J Natl Cancer Inst Monogr, 31, 14, 10.1093/oxfordjournals.jncimonographs.a003476 · DOI · Paper page
  13. Castle, 2009, Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. Proyecto Epidemiologico Guanacaste (PEG) Group, BMJ, 339, 10.1136/bmj.b2569 · DOI · Paper page
  14. Kjaer, 2010, Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence, J Natl Cancer Inst, 102, 1478, 10.1093/jnci/djq356 · DOI · Paper page
  15. Wheeler, 2009, Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States, J Natl Cancer Inst, 101, 475, 10.1093/jnci/djn510 · DOI · Paper page
  16. Bosch, 2003, Chapter 1: Human papillomavirus and cervical cancer–burden and assessment of causality, J Natl Cancer Inst Monogr, 31, 3, 10.1093/oxfordjournals.jncimonographs.a003479 · DOI · Paper page
  17. Xi, 2009, Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load, Cancer Epidemiol Biomarkers Prev, 18, 3490, 10.1158/1055-9965.EPI-09-0763 · DOI
  18. Moscicki, 2006, Chapter 5: Updating the natural history of HPV and anogenital cancer, Vaccine, 24, 42, 10.1016/j.vaccine.2006.06.018 · DOI · Paper page
  19. Dunne, 2007, Prevalence of HPV infection among females in the United States, JAMA, 297, 813, 10.1001/jama.297.8.813 · DOI · Paper page
  20. Clavel, 2001, Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women, Br J Cancer, 84, 1616, 10.1054/bjoc.2001.1845 · DOI · Paper page
  21. Kulasingam, 2002, Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral, JAMA, 288, 1749, 10.1001/jama.288.14.1749 · DOI · Paper page
  22. Castle, 2009, Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting, Obstet Gynecol, 113, 595, 10.1097/AOG.0b013e3181996ffa · DOI
  23. Plummer, 2007, A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. ALTS Group, J Infect Dis, 195, 1582, 10.1086/516784 · DOI · Paper page
  24. Rodriguez, 2008, Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. Proyecto Epidemiologico Guanacaste Group, J Natl Cancer Inst, 100, 513, 10.1093/jnci/djn044 · DOI · Paper page
  25. Woodman, 2001, Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study, Lancet, 357, 1831, 10.1016/S0140-6736(00)04956-4 · DOI · Paper page
  26. Winer, 2003, Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students [published erratum appears in Am J Epidemiol, Am J Epidemiol, 157, 218, 10.1093/aje/kwf180 · DOI · Paper page
  27. Insinga, 2007, Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives, Cancer Epidemiol Biomarkers Prev, 16, 709, 10.1158/1055-9965.EPI-06-0846 · DOI
  28. Brown, 2005, A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women, J Infect Dis, 191, 182, 10.1086/426867 · DOI · Paper page
  29. Moscicki, 1998, The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women, J Pediatr, 132, 277, 10.1016/S0022-3476(98)70445-7 · DOI · Paper page
  30. Moscicki, 2004, Regression of low-grade squamous intra-epithelial lesions in young women, Lancet, 364, 1678, 10.1016/S0140-6736(04)17354-6 · DOI · Paper page
  31. Moore, 2007, Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes, Am J Obstet Gynecol, 197, 141, 10.1016/j.ajog.2007.03.029 · DOI
  32. Fuchs, 2007, Management of cervical intraepithelial neoplasia 2 in adolescent and young women, J Pediatr Adolesc Gynecol, 20, 269, 10.1016/j.jpag.2007.04.012 · doi:10.1016/j.jpag.2007.04.012
  33. Chen, 2011, Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. CBCSP-HPV Study Group, J Natl Cancer Inst, 103, 1387, 10.1093/jnci/djr283 · DOI · Paper page
  34. Massad, 2013, 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 2012 ASCCP Consensus Guidelines Conference [published erratum appears in J Low Genit Tract Dis 2013;17:367], J Low Genit Tract Dis, 17, S1, 10.1097/LGT.0b013e318287d329 · DOI · Paper page
  35. Castle, 2007, The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report, Am J Clin Pathol, 127, 805, 10.1309/PT3PNC1QL2F4D2VL · DOI · Paper page
  36. Carreon, 2007, CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples, Int J Gynecol Pathol, 26, 441, 10.1097/pgp.0b013e31805152ab · DOI · Paper page
  37. Darragh, 2012, The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Members of LAST Project Work Groups [published erratum appears in J Low Genit Tract Dis 2013;17:368], J Low Genit Tract Dis, 16, 205, 10.1097/LGT.0b013e31825c31dd · DOI · Paper page
  38. McCredie, 2008, Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study, Lancet Oncol, 9, 425, 10.1016/S1470-2045(08)70103-7 · DOI · Paper page
  39. Gungorduk, 2015, Does lubrication of the vaginal speculum reduce pain during a gynecologic oncology examination?, Eur J Obstet Gynecol Reprod Biol, 184, 84, 10.1016/j.ejogrb.2014.11.006 · doi:10.1016/j.ejogrb.2014.11.006
  40. Simavli, 2014, The role of gel application in decreasing pain during speculum examination and its effects on papanicolaou smear results, Arch Gynecol Obstet, 289, 809, 10.1007/s00404-013-3047-x · DOI
  41. Uygur, 2012, Association of speculum lubrication with pain and Papanicolaou test accuracy, J Am Board Fam Med, 25, 798, 10.3122/jabfm.2012.06.120021 · DOI
  42. Hill, 2012, Effect of lubricating gel on patient comfort during vaginal speculum examination: a randomized controlled trial, Obstet Gynecol, 119, 227, 10.1097/AOG.0b013e3182426275 · DOI
  43. AbdullGaffar, 2010, Lubricant, mucus, and other contaminant materials as a potential source of interpretation errors in ThinPrep cervical cytology, J Low Genit Tract Dis, 14, 22, 10.1097/LGT.0b013e3181ab4584 · doi:10.1097/lgt.0b013e3181ab4584
  44. Charoenkwan, 2008, Effects of gel lubricant on cervical cytology, Acta Cytol, 52, 654, 10.1159/000325617 · doi:10.1159/000325617
  45. Amies, 2002, The effect of vaginal speculum lubrication on the rate of unsatisfactory cervical cytology diagnosis, Obstet Gynecol, 100, 889
  46. Harer, 2002, Lubrication of the vaginal introitus and speculum does not affect Papanicolaou smears, Obstet Gynecol, 100, 887
  47. Gilson, 2006, Does gel affect cytology or comfort in the screening papanicolaou smear?, J Am Board Fam Med, 19, 340, 10.3122/jabfm.19.4.340 · doi:10.3122/jabfm.19.4.340
  48. Griffith, 2005, Vaginal speculum lubrication and its effects on cervical cytology and microbiology, Contraception, 72, 60, 10.1016/j.contraception.2005.01.004 · doi:10.1016/j.contraception.2005.01.004
  49. Allan, 2011, Papanicolaou tests: does lubricant reduce the quality or adequacy?, Can Fam Physician, 57, 309
  50. Arbyn, 2008, Liquid compared with conventional cervical cytology: a systematic review and meta- analysis, Obstet Gynecol, 111, 167, 10.1097/01.AOG.0000296488.85807.b3 · DOI · Paper page
  51. Siebers, 2009, Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial [published erratum appears in JAMA 2009;302:2322], JAMA, 302, 1757, 10.1001/jama.2009.1569 · DOI · Paper page
  52. Schiffman, 2010, A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia, Cancer Res, 70, 3159, 10.1158/0008-5472.CAN-09-4179 · DOI · Paper page
  53. Kinney, 2010, Special commentary: patient safety and the next generation of HPV DNA tests, Am J Clin Pathol, 134, 193, 10.1309/AJCPRI8XPQUEAA3K · DOI
  54. Meijer, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older, Int J Cancer, 124, 516, 10.1002/ijc.24010 · DOI · Paper page
  55. Stoler, 2007, The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. American Society for Colposcopy and Cervical Pathology, Am J Clin Pathol, 127, 335, 10.1309/RNF3C01JKADQCLKP · doi:10.1309/rnf3c01jkadqclkp
  56. Brotherton, 2011, Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study, Lancet, 377, 2085, 10.1016/S0140-6736(11)60551-5 · DOI · Paper page
  57. Brown, 2009, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years, J Infect Dis, 199, 926, 10.1086/597307 · DOI · Paper page
  58. Chatterjee, 2014, The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon, Expert Rev Vaccines, 13, 1279, 10.1586/14760584.2014.963561 · DOI
  59. Petrosky, 2015, Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep, 64, 300
  60. 2015, Committee Opinion No. 641. American College of Obstetricians and Gyne-cologists, Obstet Gynecol, 126, e38
  61. Elbasha, 2007, Model for assessing human papillomavirus vaccination strategies, Emerg Infect Dis, 13, 28, 10.3201/eid1301.060438 · DOI · Paper page
  62. Stout, 2008, Trade-offs in cervical cancer prevention: balancing benefits and risks, Arch Intern Med, 168, 1881, 10.1001/archinte.168.17.1881 · DOI
  63. Insinga, 2007, Abnormal outcomes following cervical cancer screening: event duration and health utility loss, Med Decis Making, 27, 414, 10.1177/0272989X07302128 · DOI
  64. Maissi, 2005, The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up, Br J Cancer, 92, 990, 10.1038/sj.bjc.6602411 · DOI
  65. Kinney, 2015, Increased cervical cancer risk associated with screening at longer intervals, Obstet Gynecol, 125, 311, 10.1097/AOG.0000000000000632 · doi:10.1097/aog.0000000000000632
  66. Barnholtz-Sloan, 2009, Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity, Cancer Causes Control, 20, 1129, 10.1007/s10552-009-9317-z · DOI
  67. Moscicki, 2010, Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women, J Low Genit Tract Dis, 14, 73, 10.1097/LGT.0b013e3181cec411 · DOI
  68. Watson, 2008, Burden of cervical cancer in the United States, 1998-2003, Cancer, 113, 2855, 10.1002/cncr.23756 · DOI · Paper page
  69. Sasieni, 2009, Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data [published erratum appears in BMJ, 339
  70. Winer, 2008, Risk of female human papillomavirus acquisition associated with first male sex partner, J Infect Dis, 197, 279, 10.1086/524875 · DOI · Paper page
  71. 2013, Committee Opinion No. 582. American College of Obstetricians and Gynecologists, Obstet Gynecol, 122, 1378
  72. Wright, 2005, Cervical dysplasia in adolescents, Obstet Gynecol, 106, 115, 10.1097/01.AOG.0000165822.29451.54 · DOI
  73. Kyrgiou, 2006, Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis, Lancet, 367, 489, 10.1016/S0140-6736(06)68181-6 · DOI · Paper page
  74. Bruinsma, 2011, The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis, BJOG, 118, 1031, 10.1111/j.1471-0528.2011.02944.x · DOI · Paper page
  75. Conner, 2014, Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis, Obstet Gynecol, 123, 752, 10.1097/AOG.0000000000000174 · DOI
  76. 2014, Committee Opinion No. 598. American College of Obstetricians and Gyne-cologists, Obstet Gynecol, 123, 1143
  77. Arbyn, 2006, Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses, Vaccine, 24, 78, 10.1016/j.vaccine.2006.05.117 · DOI · Paper page
  78. Ronco, 2006, Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. New Technologies for Cervical Cancer Working Group, J Natl Cancer Inst, 98, 765, 10.1093/jnci/djj209 · DOI · Paper page
  79. Dillner, 2008, Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening. Joint European Cohort Study, BMJ, 337, a1754, 10.1136/bmj.a1754 · DOI · Paper page
  80. Katki, 2013, Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines, J Low Genit Tract Dis, 17, S28, 10.1097/LGT.0b013e318285423c · DOI · Paper page
  81. Rijkaart, 2012, Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial, Lancet Oncol, 13, 78, 10.1016/S1470-2045(11)70296-0 · DOI · Paper page
  82. Ronco, 2010, Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. New Technologies for Cervical Cancer screening (NTCC) Working Group, Lancet Oncol, 11, 249, 10.1016/S1470-2045(09)70360-2 · DOI · Paper page
  83. Naucler, 2007, Human papillomavirus and Papanicolaou tests to screen for cervical cancer [published erratum appears in N Engl J Med 2008;359:1637], N Engl J Med, 357, 1589, 10.1056/NEJMoa073204 · DOI · Paper page
  84. 2007, collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. International Collaboration of Epidemiological Studies of Cervical Cancer [published erratum appears in Int J Cancer 2007; 120:2525], Int J Cancer, 120, 885
  85. Katki, 2011, Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice [published erratum appears in Lancet Oncol 2011;12:722], Lancet Oncol, 12, 663, 10.1016/S1470-2045(11)70145-0 · DOI · Paper page
  86. Anttila, 2010, Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme, BMJ, 340, 10.1136/bmj.c1804 · DOI · Paper page
  87. 2012, Committee Opinion No. 534. American College of Obstetricians and Gynecologists, Obstet Gynecol, 120, 421
  88. Sasieni, 2003, Benefit of cervical screening at different ages: evidence from the UK audit of screening histories, Br J Cancer, 89, 88, 10.1038/sj.bjc.6600974 · DOI · Paper page
  89. 1986, duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes, Br Med J (Clin Res Ed), 293, 659, 10.1136/bmj.293.6548.659 · DOI · Paper page
  90. Sawaya, 2000, Frequency of cervical smear abnormalities within 3 years of normal cytology, Obstet Gynecol, 96, 219, 10.1097/00006250-200008000-00012 · DOI
  91. Eddy, 1987, The frequency of cervical cancer screening. Comparison of a mathematical model with empirical data, Cancer, 60, 1117, 10.1002/1097-0142(19870901)60:5<1117::AID-CNCR2820600533>3.0.CO;2-H · doi:10.1002/1097-0142(19870901)60:5<1117::aid-cncr2820600533>3.0.co;2-h
  92. Miller, 2003, Screening interval and risk of invasive squamous cell cervical cancer, Obstet Gynecol, 101, 29, 10.1097/00006250-200305000-00043 · doi:10.1097/00006250-200305000-00043
  93. Sawaya, 2001, Advancing age and cervical cancer screening and prognosis, J Am Geriatr Soc, 49, 1499, 10.1046/j.1532-5415.2001.4911243.x · doi:10.1046/j.1532-5415.2001.4911243.x
  94. Sawaya, 2000, The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS), Ann Intern Med, 133, 942, 10.7326/0003-4819-133-12-200012190-00009 · DOI
  95. Stokes-Lampard, 2006, Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature, BJOG, 113, 1354, 10.1111/j.1471-0528.2006.01099.x · DOI
  96. Kalogirou, 1997, Vaginal intraepithelial neoplasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix, Eur J Gynaecol Oncol, 18, 188
  97. Sillman, 1997, Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management, Am J Obstet Gynecol, 176, 93, 10.1016/S0002-9378(97)80018-X · DOI · Paper page
  98. Wright, 2015, Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test, Gynecol Oncol, 136, 189, 10.1016/j.ygyno.2014.11.076 · DOI · Paper page
  99. 2013, Management of abnormal cervical cancer screening test results and cervical cancer precursors. Practice Bulletin No. 140. American College of Obstetricians and Gynecologists, Obstet Gynecol, 122, 1338, 10.1097/01.AOG.0000438960.31355.9e · DOI
  100. Katki, 2013, Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results, J Low Genit Tract Dis, 17, S36, 10.1097/LGT.0b013e3182854253 · DOI
  101. Khan, 2005, The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst, 97, 1072, 10.1093/jnci/dji187 · DOI · Paper page
  102. Wright, 2011, Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group, Am J Clin Pathol, 136, 578, 10.1309/AJCPTUS5EXAS6DKZ · DOI · Paper page
  103. Lehtinen, 2012, Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. HPV PATRICIA Study Group [published erratum appears in Lancet Oncol 2012;13:e1], Lancet Oncol, 13, 89, 10.1016/S1470-2045(11)70286-8 · DOI · Paper page
  104. 2007, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. FUTURE II Study Group, N Engl J Med, 356, 1915, 10.1056/NEJMoa061741 · DOI · Paper page
  105. Dorell, 2011, Human papillomavirus vaccination series initiation and completion, 2008-2009 [published erratum appears in Pediatrics 2012;130:166–8], Pediatrics, 128, 830, 10.1542/peds.2011-0950 · DOI · Paper page
  106. Soutter, 2006, Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia, Int J Cancer, 118, 2048, 10.1002/ijc.21604 · DOI · Paper page

Cited by

See all 175

Metadata

Venue
Obstetrics & Gynecology
Published
2016-10
Volume
128
Issue
4
Pages
e111-e130
ISSN
0029-7844 (ISSN-L)
OpenAlex
W4211002643
Cited by
175
References
2
FWCI
16.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ACOG. https://app.cochat.ai/papers/10.1097/aog.0000000000001708
The paper
ACOG. (2016). Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000001708

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.